Compare Ginkgo Bioworks Holdings Inc (DNA) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Entegris Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.01 (market cap $590.53M), while Entegris Inc trades at $135.03 (market cap $21.42B). The key difference: Entegris Inc is far larger — about 36.3× Ginkgo Bioworks Holdings Inc's market cap, and Entegris Inc pays a 0.28% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | ENTG | |
|---|---|---|
Market Cap | $590.53M | $21.42B |
Sector | Health | Technology |
52-Week High | $16.14 | $184.00 |
52-Week Low | $5.48 | $68.80 |
Enterprise Value | $627.78M | $24.73B |
Dividend Yield | — | 0.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
ENTG trades at $136.27, down 6.25% over 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a high P/E of 78.77 but strong recent earnings beats. Revenue remains stable at $3.2B with improving net margins. Analyst consensus is bullish with a $178.40 price target, representing 31% upside potential. Recent developments include a new CFO appointment and strategic licensing agreements in semiconductor technology.
ENTG presents a compelling growth story in semiconductor materials with AI-driven demand catalysts, though premium valuation and technical weakness create near-term headwinds. The company's positioning in advanced chip manufacturing and consistent earnings performance support long-term upside, while current price levels offer entry opportunity below analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
